Fosamprenavir-13C6

Fosamprenavir-13C6 is the 13C-labeled Fosamprenavir (HY-78726) . Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430) . Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection[1][2][3].

Product Specifications

Product Name Alternative

Amprenavir phosphate-13C6; GW 433908-13C6

UNSPSC

12352005

Target

Drug Intermediate; HIV; HIV Protease; Isotope-Labeled Compounds

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Others

Applications

COVID-19-anti-virus

Field of Research

Infection

Smiles

O=C(O[C@@H]1COCC1)N[C@@H](CC2=CC=CC=C2)[C@H](OP(O)(O)=O)CN(S(=O)([13C]3=[13C][13C]=[13C](N)[13C]=[13C]3)=O)CC(C)C

Molecular Formula

C19 13C6H32N3O9PS

Molecular Weight

587.53

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Hester EK, et al. Fosamprenavir: drug development for adherence. Ann Pharmacother. 2006 Jul-Aug;40 (7-8) :1301-10.|[3]Johnston N, et al. Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model. Laryngoscope. 2023 Jan;133 Suppl 1 (Suppl 1) :S1-S11.